Biogen Quarterly Cash Flow Statement
NASDAQ: BIIBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Biogen free cash flow
In the quarter ended Mar 31, 2026, Biogen generated $645.5 million of operating cash flow and spent $51.2 million on capital expenditures. That left free cash flow of $594.3 million, a free-cash-flow margin of 24.0% of revenue. Free cash flow was up 167.5% from the prior year's $222.2 million.
Summary generated from market data by MetaCap's automated system. Methodology
Biogen cash flow statement (quarterly)
| Quarter (USD) | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q2 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 319.50M | -48.90M | 466.50M | 634.80M | 240.50M | 266.70M | 388.50M | 583.60M | 393.40M | 248.90M | -68.30M | 593.30M |
| Net Income growth (YoY) | +32.85% | -118.34% | +20.08% | +8.77% | -38.87% | +7.15% | — | -1.63% | +1.50% | -54.70% | -106.02% | -43.96% |
| Depreciation & Amortization | 204.40M | 200.20M | 202.20M | 194.30M | 183.20M | 184.00M | 182.80M | 158.90M | 147.50M | 140.10M | 125.00M | 117.40M |
| Stock-Based Compensation | 84.00M | 59.60M | 75.30M | 74.90M | 81.00M | 75.10M | 72.70M | 70.60M | 72.80M | 54.90M | 62.20M | 71.50M |
| Change in Working Capital | -127.00M | 174.40M | 278.60M | -108.10M | -238.50M | 42.40M | 12.20M | -49.00M | -254.80M | -591.50M | 451.20M | 74.90M |
| Operating Cash Flow | 645.50M | 511.90M | 1.27B | 160.90M | 259.30M | 760.90M | 935.60M | 625.80M | 553.20M | 12.50M | 592.40M | 487.00M |
| Capital Expenditures | -51.20M | -43.90M | -46.20M | -26.60M | -37.10M | -39.30M | -35.00M | -33.50M | -45.90M | -65.20M | -74.20M | -71.00M |
| Investing Cash Flow | -209.50M | -1.23B | -35.10M | -57.00M | -47.30M | -18.60M | -1.18B | 466.50M | -66.00M | -652.30M | -1.74B | -753.50M |
| Share Repurchases | — | — | — | — | — | — | — | — | — | 0 | 0 | — |
| Debt Issued | — | 0 | -300.00K | — | — | 0 | 0 | — | — | 0 | — | — |
| Debt Repaid | — | 0 | 0 | -1.75B | 0 | 0 | 0 | -250.00M | -400.00M | -650.00M | -159.90M | 0 |
| Financing Cash Flow | -43.80M | -137.00M | -130.20M | -11.70M | -23.00M | 7.90M | -6.60M | -245.20M | -439.60M | -646.10M | 848.60M | -9.80M |
| Net Change in Cash | 392.20M | -856.80M | 1.11B | 92.20M | 189.00M | 750.20M | -252.10M | 847.10M | 47.60M | -1.29B | -301.20M | -276.30M |
| Free Cash Flow | 594.30M | 468.00M | 1.23B | 134.30M | 222.20M | 721.60M | 900.60M | 592.30M | 507.30M | -52.70M | 518.20M | 416.00M |
This table shows 12 quarterly periods of Biogen's cash flow statement, from Q1 2026 back to Q2 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BIIB's reporting calendar. What is a cash flow statement?